Catalyst overview
Research summary
This catalyst tracks a Phase 1b update for ARR-217/MRG007 (CDH17-Targeted ADC) in Gastrointestinal Malignancies. The expected timing is based on the latest available company guidance and may change.
03/05/26:- ARR-217 CDH17-targeted ADC Phase 1 dose escalation ongoing in gastrointestinal malignancies; complete escalation and start optimization H2 2026. 05/11/26:- ARR-217 IND cleared; first patient dosed March 2026; Phase 1 GI malignancy dose escalation ongoing. 08/12/26:- ARR-217 entered Phase 1b dose optimization in gastrointestinal malignancies. Initial Phase 1 data will be presented at a future medical conference.
Verification
Confirm timing and program details against the company announcement or filing.